Election

The New Reality for Pharma Marketers is Drug Pricing

The New Reality for Pharma Marketers is Drug Pricing

By

My hope is that all of us do a better job of focusing on value.

Five things for pharma marketers to know: Tuesday, November 29, 2016

Five things for pharma marketers to know: Tuesday, November 29, 2016

By

Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money

10 Things for Trump to Consider When It Comes to Healthcare

10 Things for Trump to Consider When It Comes to Healthcare

Peter Pitts calls for Trump to eliminate the Independent Payment Advisory Board and direct the FDA to issue guidance on off-label communications.

Five things for pharma marketers to know: Monday, November 14, 2016

Five things for pharma marketers to know: Monday, November 14, 2016

By

J&J's experimental RA drug has mixed results in clinical trial; Novartis reportedly considers buying generics maker; Donald Trump names healthcare transition team leader

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

What's Next for the FDA During the Trump Administration

What's Next for the FDA During the Trump Administration

By

Expect major changes in the way the FDA does business with drug companies after the Trump administration takes over in January.

Five things for pharma marketers to know: Friday, November 11, 2016

Five things for pharma marketers to know: Friday, November 11, 2016

By

Trump says he will reform the FDA; pharmaceutical M&A expected to pick up; superbug causing infections in cystic-fibrosis patients

The drug industry wins pricing battle in California, likely to fare better with Trump

The drug industry wins pricing battle in California, likely to fare better with Trump

By

But experts say that drug pricing will remain a significant issue for the industry going forward into a non-election year.

Five things for pharma marketers to know: Wednesday, November 9, 2016

Five things for pharma marketers to know: Wednesday, November 9, 2016

By

Trump, a critic and supporter of pharma, wins election; pharma's futures rise in election's wake; drug-pricing measure in California likely to be defeated

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

By

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

J&J exec calls California pricing measure 'misguided'

J&J exec calls California pricing measure 'misguided'

By

Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.

Trump or Clinton? Either May Lead to Better Mental Healthcare

Trump or Clinton? Either May Lead to Better Mental Healthcare

Despite political rifts that have blocked progress on so many other fronts, Congress has managed to lay the groundwork for clear steps forward in mental health.

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election

Policymakers respond to a crisis and every crisis has to have a villain. Unfortunately, today pharma is the villain.

Clinton or Trump? Either Way, Change Is Coming

Clinton or Trump? Either Way, Change Is Coming

Donald Trump and Hillary Clinton offer clear contrasts on the issues of the Affordable Care Act, entitlement reform, and drug pricing.

Clinton campaign ad targets Valeant, drug repricing

Clinton campaign ad targets Valeant, drug repricing

By

Presidential candidate Hillary Clinton said she would go after "predatory" pharma companies in new ad spot.

Clinton vows price controls, generic biologics in healthcare plan

Clinton vows price controls, generic biologics in healthcare plan

Sen. Hillary Clinton unveiled her healthcare plan, promising to cover all Americans if elected president - and taking a few swipes at the pharmaceutical and insurance industries.

OPINION

Email Newsletters